keyword
MENU ▼
Read by QxMD icon Read
search

Her-2

keyword
https://www.readbyqxmd.com/read/28454423/the-nutritional-herb-epimedium-grandiflorum-inhibits-the-growth-in-a-model-for-the-luminal-a-molecular-subtype-of-breast-cancer
#1
Nitin T Telang, Gou Li, Meena Katdare, Daniel W Sepkovic, H Leon Bradlow, George Y C Wong
The Luminal A subtype of breast cancer expresses the estrogen receptor (ER)-α and progesterone receptor (PR), but not the human epidermal growth factor receptor (HER)-2 oncogene. This subtype of breast cancer responds to endocrine therapy involving the use of selective estrogen receptor modulators and/or inhibitors of estrogen biosynthesis. However, these therapeutic agents are frequently associated with long-term systemic toxicity and acquired tumor resistance, emphasizing the need to identify non-toxic alternative treatments for chemo-endocrine therapy responsive breast cancer...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454407/downregulation-of-npm-expression-by-her-2-reduces-resistance-of-gastric-cancer-to-oxaliplatin
#2
Zhenni Sun, Lu Yue, Zan Shen, Yong Li, Aihua Sui, Tianjun Li, Qian Tang, Ruyong Yao, Yongning Sun
Nucleophosmin (NPM) and human epidermal growth factor receptor-2 (Her-2) are abnormally expressed in various types of human malignant tumors, including gastric cancer, and have been closely associated with cancer chemoresistance. However, their interaction and roles in oxaliplatin resistance are not fully understood. Therefore, the present study aimed to elucidate the relationship between NPM and Her-2 in gastric cancer cell lines and clinical samples, and further investigated their role in the resistance of gastric cancer to oxaliplatin...
April 2017: Oncology Letters
https://www.readbyqxmd.com/read/28454227/chromobox-homolog-2-protein-a-novel-biomarker-for-predicting-prognosis-and-taxol-sensitivity-in-patients-with-breast-cancer
#3
Wang Yang Chen, Xian Yu Zhang, Tong Liu, Yang Liu, Ya Shuang Zhao, Da Pang
Polycomb group (PcG) complexes modify histones to silence tumor suppressor genes, which exhibit an important function in tumorigenesis and progression. The chromobox (Cbx) protein family is a critical component of PcG-mediated repression. Cbx2, a member of the Cbx protein family, is hypothesized to exhibit a vital role in breast cancer. In the present study, immunohistochemical analysis using tissue microarrays was performed to determine the levels of Cbx2 protein expression in breast cancer. The association between Cbx2 expression and the clinical features and prognosis of 455 breast cancer patients was analyzed...
March 2017: Oncology Letters
https://www.readbyqxmd.com/read/28445991/human-epidermal-growth-factor-receptor-2-expression-is-more-important-than-bacillus-calmette-guerin-treatment-in-predicting-the-outcome-of-t1g3-bladder-cancer
#4
Luigi Cormio, Francesca Sanguedolce, Antonella Cormio, Paolo Massenio, Maria Carmela Pedicillo, Simona Cagiano, Giuseppe Calò, Vincenzo Pagliarulo, Giuseppe Carrieri, Pantaleo Bufo
In the present study we tested the role of Human Epidermal Growth Factor Receptor-2 (HER-2) expression, as assayed by immunohistochemistry, in predicting recurrence and progression in 67 patients with T1G3 BC having undergone transurethral resection of bladder tumor (TURBT) alone (33) or TURBT + Bacillus Calmette Guerin (BCG) instillations (34). All patients had a negative restaging TURBT within 4 months after the first TURBT. At median follow-up of 75.7 months, the overall disease-free and progression-free rates were 35...
April 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28443693/confounder-factors-masking-a-leydig-cell-ovarian-tumor-in-a-post-menopausal-woman-treated-for-androgen-positive-receptor-breast-cancer
#5
Felipe Scipião Moura, Flávia A Costa-Barbosa, Sydney Correia Leao, Sergio Mancini Nicolau, Claudio E Kater, Patrícia T Monteagudo
Post-menopause hyperandrogenism is a condition that needs careful evaluation. Aromatase inhibitors (AI), which are important in the management of positive estrogen breast cancer, and chronic kidney disease (CKD) can puzzle the evaluation of this condition. A postmenopause female with type-2 diabetes and advanced CKD was attended due to progressive virilization, which has started after the introduction of an AI for breast cancer 5 years earlier. Clinical and radiological investigation has confirmed a pure Leydig cell tumor as source of hyperandrogenism...
April 26, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/28441706/a-comprehensive-model-for-predicting-recurrence-and-survival-in-cases-of-chinese-postoperative-invasive-breast-cancer
#6
Xianhe Xie, Yanfen Hu, Chao Jing, Shuimei Luo, Yunfu Lv, Haitao Yang, Lina Li, Huijuan Chen, Wanzun Lin, Weili Zheng
We investigated relationships between clinical pathologic data, molecular biomarkers and prognosis of invasive breast cancer based on a Chinese population. Immunohistochemistry (IHC) was used to assess the status of ER, PR, HER-2 and Ki-67, with fluorescence in situ hybridization (FISH) performed to further confirm HER-2 positivity with an equivocal result (IHC 2+). Subsequently, Kaplan-Meier univariate and multivariate COX regression analyses of ER, PR, HER-2, Ki-67, clinical features, therapeutic status and follow-up data were performed according to the establishment principle of the Nottingham prognostic index (NPI)...
March 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28438091/analytic-response-curves-of-clinical-breast-cancer-ihc-tests
#7
Kodela Vani, Seshi R Sompuram, Anika K Schaedle, Anuradha Balasubramanian, Steven A Bogen
An important limitation in the field of immunohistochemistry (IHC) is the inability to correlate stain intensity with specific analyte concentrations. Clinical immunohistochemical tests are not described in terms of analytic response curves, namely, the analyte concentrations in a tissue sample at which an immunohistochemical stain (1) is first visible, (2) increases in proportion to the analyte concentration, and (3) ultimately approaches a maximum color intensity. Using a new immunostaining tool ( IHControls), we measured the analytic response curves of the major clinical immunohistochemical tests for human epidermal growth factor receptor type II (HER-2), estrogen receptor (ER), and progesterone receptor (PR)...
May 2017: Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society
https://www.readbyqxmd.com/read/28429100/conversion-of-hormone-and-her-2-receptor-in-metachronous-neck-metastases-from-breast-carcinoma
#8
Andreas Nauroth, Matthias Kalder, Marion Rössler, Gunnar Wichmann, Andreas Dietz, Susanne Wiegand
PURPOSE: Metastases are a common event in breast cancer. The expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER-2) is essential for therapy and prognosis, and their conversion during disease progression potentially affects the treatment regimen. The aim was to analyze the estrogen, progesterone and HER-2 receptor expression in primary tumors and metachronous neck metastases from patients with breast cancer. METHODS: A retrospective analysis of 27 patients with breast cancer and metachronous neck metastasis was performed...
April 20, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28426105/the-prevalence-and-clinical-relevance-of-tumor-infiltrating-lymphocytes-tils-in-ductal-carcinoma-in-situ-of-the-breast
#9
G Pruneri, M Lazzeroni, V Bagnardi, G B Tiburzio, N Rotmensz, A DeCensi, A Guerrieri-Gonzaga, A Vingiani, G Curigliano, S Zurrida, F Bassi, R Salgado, G Van den Eynden, S Loi, C Denkert, B Bonanni, G Viale
Background: Tumor-infiltrating lymphocytes (TILs) are a robust prognostic adjunct in invasive breast cancer, but their clinical role in ductal carcinoma in situ (DCIS) has not been ascertained. Patients and methods: We evaluated the prevalence and clinical relevance of TILs in a well annotated series of 1488 consecutive DCIS women with a median follow-up of 8.2 years. Detailed criteria for TILs evaluation were pre-defined involving the International Immuno-Oncology Biomarker Working Group...
February 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28424200/whole-exome-sequencing-of-metaplastic-breast-carcinoma-indicates-monoclonality-with-associated-ductal-carcinoma-component
#10
Bracha Avigdor, Katie Beierl, Christopher D Gocke, Daniel Zabransky, Karen Cravero, Kelly Kyker-Snowman, Berry Button, David Chu, Sarah Croessmann, Rory L Cochran, Roisin Connolly, Ben Ho Park, Ashley Cimino-Mathews, Sarah J Wheelan
Although most human cancers display a single histology, there are unusual cases where two or more distinct tissue types present within a primary tumor. One such example is metaplastic breast carcinoma, a rare but aggressive cancer with a heterogenous histology, including squamous, chondroid, and spindle cells. Metaplastic carcinomas often contain an admixed conventional ductal invasive or in situ mammary carcinoma component, and are typically triple-negative for estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER-2) amplification/overexpression...
April 19, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28423522/prss3-is-a-prognostic-marker-in-invasive-ductal-carcinoma-of-the-breast
#11
Li Qian, Xiangxiang Gao, Hua Huang, Shumin Lu, Yin Cai, Yu Hua, Yifei Liu, Jianguo Zhang
OBJECTIVE: Serine protease 3 (PRSS3) is an isoform of trypsinogen, and plays an important role in the development of many malignancies. The objective of this study was to determine PRSS3 mRNA and protein expression levels in invasive ductal carcinoma of the breast and normal surrounding tissue samples. RESULTS: Both PRSS3 mRNA and protein levels were significantly higher in invasive ductal carcinoma of the breast tissues than in normal or benign tissues (all P < 0...
March 28, 2017: Oncotarget
https://www.readbyqxmd.com/read/28421181/mct1-in-invasive-ductal-carcinoma-monocarboxylate-metabolism-and-aggressive-breast-cancer
#12
Jennifer M Johnson, Paolo Cotzia, Roberto Fratamico, Lekha Mikkilineni, Jason Chen, Daniele Colombo, Mehri Mollaee, Diana Whitaker-Menezes, Marina Domingo-Vidal, Zhao Lin, Tingting Zhan, Madalina Tuluc, Juan Palazzo, Ruth C Birbe, Ubaldo E Martinez-Outschoorn
Introduction: Monocarboxylate transporter 1 (MCT1) is an importer of monocarboxylates such as lactate and pyruvate and a marker of mitochondrial metabolism. MCT1 is highly expressed in a subgroup of cancer cells to allow for catabolite uptake from the tumor microenvironment to support mitochondrial metabolism. We studied the protein expression of MCT1 in a broad group of breast invasive ductal carcinoma specimens to determine its association with breast cancer subtypes and outcomes. Methods: MCT1 expression was evaluated by immunohistochemistry on tissue micro-arrays (TMA) obtained through our tumor bank...
2017: Frontiers in Cell and Developmental Biology
https://www.readbyqxmd.com/read/28418916/clinicopathologic-study-of-invasive-micropapillary-carcinoma-of-the-breast
#13
Shen-Li Tang, Ji-Qiao Yang, Zheng-Gui Du, Qiu-Wen Tan, Yu-Ting Zhou, Di Zhang, Qing Lv
Invasive micropapillary carcinoma (IMPC) is a rare subtype of breast carcinoma. It is presumed to be more aggressive than invasive ductal carcinoma (IDC), though it is uncertain whether the prognoses of IMPC and IDC differ. In this retrospective study, we compared the clinicopathologic characteristics and survival between 170 female patients with IMPC (pure or mixed with IDC) and 728 with pure IDC. The IMPC patients had higher clinical stages and histologic grades, higher incidences of lymphovascular invasion and axillary lymph node extracapsular extension, and a higher degree of lymph node involvement than IDC patients...
March 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28417445/chemopreventive-efficacy-of-curcumin-loaded-plga-microparticles-in-a-transgenic-mouse-model-of-her-2-positive-breast-cancer
#14
Alex E Grill, Komal Shahani, Brenda Koniar, Jayanth Panyam
Curcumin has shown promising inhibitory activity against HER-2-positive tumor cells in vitro but suffers from poor oral bioavailability in vivo. Our lab has previously developed a polymeric microparticle formulation for sustained delivery of curcumin for chemoprevention. The goal of this study was to examine the anticancer efficacy of curcumin-loaded polymeric microparticles in a transgenic mouse model of HER-2 cancer, Balb-neuT. Microparticles were injected monthly, and mice were examined for tumor appearance and growth...
April 17, 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28408326/emp1-emp-2-and-emp3-as-novel-therapeutic-targets-in-human-cancer
#15
REVIEW
Yi-Wen Wang, Hong-Ling Cheng, Ya-Rou Ding, Lien-Hsuan Chou, Nan-Haw Chow
The epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, and EMP3) belong to the peripheral myelin protein 22-kDa (PMP22) gene family, which consists of at least seven members: PMP22, EMP1, EMP2, EMP3, PERP, brain cell membrane protein 1, and MP20. This review addresses the structural and functional features of EMPs, detailing their tissue distribution and functions in the human body, their expression pattern in a variety of tumors, and highlighting the underlying mechanisms involved in carcinogenesis...
April 10, 2017: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/28405507/a-review-of-the-importance-of-immune-responses-in-luminal-b-breast-cancer
#16
REVIEW
Delia J Nelson, Briony Clark, Kylie Munyard, Vincent Williams, David Groth, Jespal Gill, Henry Preston, Arlene Chan
Historically, the immune environment was not considered an important target for breast cancer treatment. However, the association of lymphocytic infiltrates in triple negative and HER-2 over-amplified breast cancer subtypes with better outcomes, has provoked interest in evaluating the role of the immune system in the luminal B subtype that accounts for 39% of breast cancers and has a poor patient prognosis. It is unknown which immunosuppressive cell types or molecules (e.g., checkpoint molecules) are relevant, or where measurement is most informative...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28400999/mtor-function-and-therapeutic-targeting-in-breast-cancer
#17
REVIEW
Stephen H Hare, Amanda J Harvey
The mTOR pathway was discovered in the late 1970s after the compound and natural inhibitor of mTOR, rapamycin was isolated from the bacterium Streptomyces hygroscopicus. mTOR is serine/threonine kinase belonging to the phosphoinositide 3-kinase related kinase (PIKK) family. It forms two distinct complexes; mTORC1 and mTORC2. mTORC1 has a key role in regulating protein synthesis and autophagy whilst mTORC2 is involved in regulating kinases of the AGC family. mTOR signaling is often over active in multiple cancer types including breast cancer...
2017: American Journal of Cancer Research
https://www.readbyqxmd.com/read/28388580/tipe3-protein-promotes-breast-cancer-metastasis-through-activating-akt-and-nf-%C3%AE%C2%BAb-signaling-pathways
#18
Kaili Lian, Chao Ma, Chunyan Hao, Yan Li, Na Zhang, Youhai H Chen, Suxia Liu
TIPE3 (TNFAIP8L3) is the transfer protein of phosphoinositide second messengers that promote cancer. Its role in breast cancer has not been evaluated. We report here that TIPE3 protein was significantly upregulated in human breast cancer tissues as compared with adjacent non-tumor tissues from the same patients. The level of TIPE3 protein in invasive ductal carcinoma was significant higher than that in ductal carcinoma in situ (DCIS), and the level of TIPE3 in lymphatic metastasized carcinoma was higher than that in invasive ductal carcinoma from the same patients...
March 23, 2017: Oncotarget
https://www.readbyqxmd.com/read/28388298/nf-%C3%AE%C2%BAb-is-a-potential-molecular-drug-target-in-triple-negative-breast-cancers
#19
Paola Poma, Manuela Labbozzetta, Natale D'Alessandro, Monica Notarbartolo
Breast cancer continues to cause significant burden in global health morbidity and mortality. Triple-negative breast cancers (TNBCs) are highly aggressive with poor prognosis and are characterized by lack of expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor (Her-2). TNBCs are often resistant to cytotoxic chemotherapy and pose major difficulty in achieving personalized medicine due to their molecular heterogeneity. There is increasing evidence that the aberrant activation of nuclear factor (NF)-κB signaling is a frequent characteristic of TNBCs...
April 2017: Omics: a Journal of Integrative Biology
https://www.readbyqxmd.com/read/28384967/human-epidermal-growth-factor-receptor-3-mrna-expression-as-a-prognostic-marker-for-invasive-duct-carcinoma-not-otherwise-specified
#20
Ghada Ezat Hammoda, Sally Mohammed El-Hefnawy, Asmaa Gaber Abdou, Rania Abdallah Abdallah
INTRODUCTION: Breast cancer is the most common cancer in women and the Erythroblastosis Oncogene B(ErbB) receptor family holds crucial role in its pathogenesis. Human Epidermal Growth Factor Receptor 3 (HER-3) gene over expression in breast tissue has been associated with aggressive clinical behaviour and bad prognosis. AIM: To evaluate HER-3 mRNA expression level as a prognostic marker for breast cancer and to correlate its level with other established prognostic parameters...
February 2017: Journal of Clinical and Diagnostic Research: JCDR
keyword
keyword
7437
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"